Stay updated on Pembrolizumab in Mets Melanoma: (C11-AMT) PET Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Mets Melanoma: (C11-AMT) PET Clinical Trial page.

Latest updates to the Pembrolizumab in Mets Melanoma: (C11-AMT) PET Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for a completed Phase 2 study of pembrolizumab and baseline C11-AMT PET imaging in metastatic melanoma. It includes study design, participation criteria, locations, outcome measures, and posted results.SummaryDifference61%

- Check18 days agoChange DetectedThe footer revision identifier was updated from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedAn NIH announcement banner says federal agencies are transitioning from “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe footer now identifies the site as revision v3.7.2 instead of v3.7.1. The page continues to show a 403 error rather than the study record.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 while the study page remains a 403 error page.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now shows a 403 Forbidden error with limited navigation, replacing the normal study content. The update appears to be a site wrapper change rather than changes to the study data itself.SummaryDifference20%

Stay in the know with updates to Pembrolizumab in Mets Melanoma: (C11-AMT) PET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Mets Melanoma: (C11-AMT) PET Clinical Trial page.